Skip to main content

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/magnify-covid19-main.2.0-1.jpg

Duke Researchers Pivot to Attack the New Coronavirus

Wed, 03/25/2020 By Mary-Russell Roberson In the race to understand the new coronavirus and generate solutions, Duke research teams are well underway. In fact, you could say they’ve been working on it for decades. Everything Duke…

Read More

Duke to lead $50 million study of COVID-19 prevention in healthcare workers

 The Patient-Centered Outcomes Research Institute has funded up to $50 million to evaluate hydroxychloroquine (HCQ) as a preventive drug for the novel coronavirus. The funding creates a new rapid-response study designed and led by the…

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/MRI-Scanncer-1.jpg

Polarean Imaging bags $10.7M fundraising; welcomes new strategic investor

Polarean Imaging PLC (LON:POLX) has conditionally raised £8.4mln (US$10.7mln) before expenses as it applies for US regulatory approval for its drug-device combination. The North Carolina-based company said the extra cash would strengthen its balance sheet while…

Read More

A New Blood Test Algorithm mPoA – Quantifying Biological Aging

People age at different rates determined by both their environment/ lifestyle and genetics. Biological aging is the gradual and progressive decline in body integrity that occurs over time eventually leading to loss of vitality or…

Read More

Bloom Science Granted Exclusive Option to License Gut Microbiome-based Therapies for ALS, Other Neurological Disorders

Bloom Science and Duke University have entered into an exclusive licensing agreement that provides the biopharmaceutical company access to the intellectual property and technology related to unique strain isolates and genetic variants of Akkermansia genus bacteria. This type of…

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/NCBC_JSink_1104_Center_550px-e1580987820765-1.jpg

NCBiotech awards $2.1M in grants, loans

The North Carolina Biotechnology Center has awarded 23 grants and loans totaling $2.1 million during the past fiscal quarter to bioscience companies, universities and non-profit organizations. The awards, made in the second quarter of the Biotech…

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/phasebio-logo.png

PhaseBio Announces Case Study Highlighting PB1046 Hemodynamic Data

Presented at the 14th Pulmonary Vascular Research Institute World Congress PhaseBio Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced presentation of data from…

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/Football_web-1.jpg

Duke Trio Named Finalists for NFL Honor

Former Duke football lettermen Clark Bulleit, Kevin Gehsmann, and Tim Skapek have been selected one of four finalists for the NFL 1st and Future innovations competition. The trio founded the company Protect3d, which revolutionizes athletic protection using 3D technology.…

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/Polarean.png

Polarean Imaging plc Announces Positive Results From Pivotal Phase III Clinical Trials

Polarean Imaging plc (AIM: POLX), a clinical stage medical imaging technology company developing a proprietary magnetic resonance imaging (MRI) drug-device combination, today announced positive top-line results from two pivotal Phase III clinical trials of the…

Read More